The pentavalent rotavirus vaccine, RotaTeq.
Vaccination against rotavirus disease has been a global preventive health priority since rotaviruses were first discovered in the 1970s. The first licensed rotavirus vaccine, RRV-TV, was removed from the market shortly after licensure because of an unexpected serious adverse event, intussusception. A pentavalent rotavirus vaccine, PRV, is the second FDA-licensed rotavirus vaccine and does not signal the risk observed with RRV-TV. The properties and large safety study results of PRV are reviewed here.
Matson
David O
DO
Graduate Program in Public Health, Eastern Virginia Medical School, Old Dominion University, Norfolk, VA 23501, USA. matsondo@evms.edu
D003968:Diarrhea, Infantile / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007114:Immunization / Q000379:methods*; D007223:Infant; D007443:Intussusception; D012401:Rotavirus / Q000276:immunology*; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D022243:Rotavirus Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated